Skip to main content

Advertisement

Table 1 Demographic and baseline characteristics of patients with NPC who were treated with famitinib

From: Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

Variables Patients (n = 20)
Age, years
 Median (IQR) 43 (39–48)
 Range 26–56
 Male sex 18 (80%)
ECOG
 0 1 (5%)
 1 19 (95%)
 Histology, WHO type III 20 (100%)
Tumour stage
 T1 1 (5%)
 T2 3 (15%)
 T3 13 (65%)
 T4 3 (15%)
Node stage
 N1 2 (10%)
 N2 13 (65%)
 N3 5 (25%)
Clinical stage
 III 12 (60%)
 IVa 3 (15%)
 IVb 5 (25%)
EBV DNA,
 ≥ 4000 copy/ml 10 (50%)
VCA-IgA
 ≥ 1:80 15 (75%)
EA-IgA
 ≥ 1:10 13 (65%)
Smokinga
 Yes 9 (45%)
Family history of NPC
 Yes 3 (15%)
  1. ECOG Eastern Cooperative Oncology Group, WHO World Health Organization, EBV DNA Epstein–Barr virus DNA, VCA viral capsid antigen, IgA immunoglobulin A, EA, early antigen, NPC nasopharyngeal carcinoma
  2. aDefined as smoking ≥100 cigarettes/lifetime